Restricted accessLetterFirst published online 2010-01
Tolerability of Two Different Combinations of Antiretroviral Drugs Including Tenofovir Used in Occupational and Nonoccupational Postexposure Prophylaxis for HIV
CardoDM, CulverDH, CiescalskiCAet al.A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med, 1997; 37:1485–1490.
2.
Ministère des Affaires Sociales, du Travail et de la Solidarité. 2003. Circulaire DGS/DHOS/DRT/DSS/SD6 A n° 2003-165 du 2 avril 2003 relative aux recommandations de mise en oeuvre d'un traitement antirétroviral après exposition au.
3.
LeeLM, HendersonDK. Tolerability of postexposure antiretrovial prophylaxis for occupational exposures to HIV. Drug Saf, 2001; 24:587–597.
4.
QuirinoT, NieroF, RicciEet al.HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther, 2000; 5:195.
5.
ParkinJM, MurphyM, AndersonJ, El-GadiS, ForsterG, PinchingAJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet, 2000; 355:722–723.
6.
RabaudC, BevilacquaS, BeguinotIet al.CISIH Nancy Lorraine Champagne-Ardenne, France. Tolerability of post-exposure zidovudine + lamivudine + nelfinavir prophylaxis of HIV infection. Clin Infect Dis, 2001; 32:1494–1495.
7.
RabaudC, BurtyC, GrandidierMet al.Tolerability of post-exposure prophylaxis of HIV infection with the combination of zidovudine/lamivudine and lopinavir/ritonavir (Combivir® + Kaletra®)Clin Infect Dis, 2005; 40:303–305.
8.
Centers for Disease Control and Prevention. Serious adverse events attribued to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997–2000. MMWR Morb Mortal Wkly Rep, 2001; 49:1153–1156.
9.
Van RompayKK, McChesneyMB, AguirreNLet al.Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infections. J Infect Dis, 2001; 184:429–438.
10.
SubbaraoS, OttenRA, RamosAet al.Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis, 2006; 194:904–911.
11.
Rapport du Groupe d'Experts 2008 sur la prise en charge médicale des patients infectées par le VIH, sous la direction du Pr Patrick Yéni. Prise en charge des situations d'exposition au risque viral. www.sante-sports.gouv.fr/IMG//pdf/18_Prise_en_charge_des_situations_d_exposition_au_risque_viral.pdf. 2009 October 26.
